medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 2

<< Back Next >>

Med Int Mex 2022; 38 (2)

Anti-COVID-19 kits: do they bring some benefit to the fight against the pandemic?

Del Carpio-Orantes L

Language: Spanish
References: 14
Page: 425-427
PDF size: 328.99 Kb.


Text Extraction

No abstract.


REFERENCES

  1. https://www.anahuac.mx/mexico/noticias/Kit-Medicocontra- el-COVID-19.

  2. http://www.imss.gob.mx/prensa/archivo/202101/038.

  3. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet 2021; 397 (10274): 605-612. doi: 10.1016/S0140- 6736(21)00149-5.

  4. https://www.recoverytrial.net/news/recovery-trial-findsaspirin- does-not-improve-survival-for-patients-hospitalised- with-covid-19

  5. López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, Díazgranados JA, Oñate JM, Chavarriaga H, Herrera S, Parra B, Libreros G, Jaramillo R, Avendaño AC, Toro DF, Torres M, Lesmes MC, Rios CA, Caicedo I. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: A randomized clinical trial. JAMA 2021; 325 (14): 1426-1435. doi: 10.1001/ jama.2021.3071.

  6. Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, Campias C, Chaparro Campias E, Achinelli F, Guglielmone HA, Ojeda J, Medina F, Farizano Salazar D, Andino G, Ruiz Diaz NE, Kawerin P, Meza E, Dellamea S, Aquino A, Flores V, Martemucci CN, Vernengo MM, Martinez SM, Segovia JE, Aguirre MG. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials 2020; 21 (1): 965. doi: 10.1186/ s13063-020-04813-1.

  7. https://www.merck.com/news/merck-statement-onivermectin- use-during-the-covid-19-pandemic/

  8. Tardif JC, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH, Lopez-Sendon J, da Luz P, Verret L, Audet S, Dupuis J, Denault A, Pelletier M, Tessier PA, Samson S, Fortin D, Tardif JD, Busseuil D, Goulet E, Lacoste C, Dubois A, Joshi AY, Waters DD, Hsue P, Lepor NE, Lesage F, Sainturet N, Roy-Clavel E, Bassevitch Z, Orfanos A, Stamatescu G, Grégoire JC, Busque L, Lavallée C, Hétu PO, Paquette JS, Deftereos SG, Levesque S, Cossette M, Nozza A, Chabot- Blanchet M, Dubé MP, Guertin MC, Boivin G; COLCORONA Investigators. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med 2021; S2213-2600 (21): 00222-8. doi: 10.1016/S2213-2600(21)00222-8.

  9. Vallianou NG, Tsilingiris D, Christodoulatos GS, Karampela I, Dalamaga M. Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic. Metabol Open 2021; 10: 100096. doi:10.1016/j. metop.2021.100096.

  10. Guimarães PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, Kalil Filho R, Junior VM, Soeiro AM, Tognon AP, Veiga VC, Martins PA, Moia DDF, Sampaio BS, Assis SRL, Soares RVP, Piano LPA, Castilho K, Momesso RGRAP, Monfardini F, Guimarães HP, Ponce de Leon D, Dulcine M, Pinheiro MRT, Gunay LM, Deuring JJ, Rizzo LV, Koncz T, Berwanger O; STOP-COVID Trial Investigators. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021: NEJMoa2101643. doi: 10.1056/NEJMoa2101643.

  11. Carpio-Orantes LD, García-Méndez S, López-Guzmán C, Zamudio-Severino GM, et al. Baricitinib in patients with severe pneumonia due to COVID-19 in Veracruz, Mexico. J Anesth Crit Care Open Access 2020; 13 (1): 17-20. DOI: 10.15406/jaccoa.2021.13.00464.

  12. https://www.recoverytrial.net/news/low-cost-dexamethasone- reduces-death-by-up-to-one-third-in-hospitalised- patients-with-severe-respiratory-complicationsof- covid-19

  13. Del Carpio-Orantes L, García-Méndez S, Sánchez-Diaz JS, Peniche-Moguel KG, Aparicio-Sánchez EE, Segura- Rodríguez OI, Aguilar-Silva A, García-Hernández O, Escobar- Huerta A, Ahumada-Zamudio A, Velasco-Caicero AR, González-Segovia O, Pacheco-Pérez EJ, Munguia-Sereno AE, Contreras-Sánchez ER, Hernández-Hernández SN, Medrano-Rios LJ, Rosas-Lozano AL. Oral anticoagulation with rivaroxaban as thromboprophylaxis in patients recovered from COVID-19 pneumonia in Veracruz, Mexico [abstract]. Res Pract Thromb Haemost 2021; 5 (Suppl 1).

  14. Mancilla-Galindo J, García-Méndez JÓ, Márquez-Sánchez J, Reyes-Casarrubias RE, Aguirre-Aguilar E, Rocha-González HI, Kammar-García A. All-cause mortality among patients treated with repurposed antivirals and antibiotics for COVID- 19 in Mexico City: A real-world observational study. EXCLI J 2021; 20: 199-222. doi: 10.17179/excli2021-3413.




2020     |     www.medigraphic.com